(Q42778982)

7 November 2017

title

Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase (English)

1 reference

7 November 2017

0 references

1 reference

3

1 reference

7 November 2017

Chi Yung Yuen

1

1 reference

7 November 2017

Wing Tak Wong

2

1 reference

7 November 2017

Siu Ling Wong

4

1 reference

7 November 2017

Chi Wai Lau

5

1 reference

7 November 2017

Jun Yu

6

1 reference

7 November 2017

Brian Tomlinson

7

1 reference

7 November 2017

Xiaoqiang Yao

8

1 reference

7 November 2017

Yu Huang

9

1 reference

7 November 2017

publication date

14 December 2010

1 reference

7 November 2017

published in

Cardiovascular Research

1 reference

7 November 2017

volume

90

1 reference

7 November 2017

issue

1

1 reference

7 November 2017

page(s)

122-129

1 reference

Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Oxidative stress and cardiovascular disease: novel tools give (free) radical insight

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Involvement of thromboxane A2 receptor in the cerebrovascular damage of salt-loaded, stroke-prone rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-indepen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Protein-protein interactions controlling nitric oxide synthases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVQ392

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1038/47254

15 July 2023

Identifiers

DOI

10.1093/CVR/CVQ392

1 reference

7 November 2017

1 reference